“…OBJETIVOS: Este estudo teve como objetivo avaliar as frequências e números absolutos de monócitos e seus subtipos: clássico (cMo), intermediário (iMo) e não clássico (ncMo) em pacientes com COVID-19, a fim de esclarecer sua relação com as alterações do sistema imunológico periférico e a gravidade da doença. MATERIAL E MÉTODOS: Este estudo incluiu um total de 30 controles saudáveis (CS) e 157 pacientes com COVID-19. …”
Enlace del recurso
Enlace del recurso

“…OBJETIVO: Avaliar possíveis diferenças no perfil linfocitário de pacientes positivos para COVID-19 com quadro  severo e  não severo da doença. MATERIAL E MÉTODOS: Pacientes admitidos no Hospital de Clínicas de Porto Alegre (HCPA) entre junho/2020 e maio/2021 foram divididos em dois grupos quanto à severidade da COVID-19; grupo severo (GS): saturação de SpO(2) < 93% em ar ambiente e/ou aumento da frequência respiratória > 30 batimentos/min e/ou relação PaO(2)/FiO(2) ≤ 300 mmHg e grupo não severo (GNS): pacientes que não se enquadraram nesses critérios. …”
Enlace del recurso
Enlace del recurso

“…PD recommendations for ASH and ASCO included: reducing or eliminating fellow membership fees, providing free access to educational materials and meetings, eliminating in-training examination fees, providing virtual sessions on career development, telehealth and wellness, virtual journal clubs, PD webinars focused on navigating fellowship issues and virtual interviews, and extending ASCO YIA funding for a second year. …”
Enlace del recurso
Enlace del recurso

“…(Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Meissa Vaccines (Other Financial or Material Support, Co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc.) …”
Enlace del recurso
Enlace del recurso

“…(Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Meissa Vaccines (Other Financial or Material Support, Co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc.) …”
Enlace del recurso
Enlace del recurso

“…Doshi, PhD, Acadia (Consultant, Advisor or Review Panel member)Allergan (Advisor or Review Panel member)Biogen (Grant/Research Support)Boehringer Ingelheim (Other Financial or Material Support, Scientific lecture)Catabasis (Consultant)Humana (Grant/Research Support)Janssen, Inc. …”
Enlace del recurso
Enlace del recurso

“…(Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Meissa Vaccines (Other Financial or Material Support, Co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc.) …”
Enlace del recurso
Enlace del recurso

“…(Other Financial or Material Support, Research Collaborator) Robert A. …”
Enlace del recurso
Enlace del recurso

“…(Employee) Richa Kalia, MS, Inovio Pharmaceuticals (Employee, Other Financial or Material Support, I have stock options with Inovio Pharmaceuticals as an employee.) …”
Enlace del recurso
Enlace del recurso

“…Objective: To determine the proportion of CML pts willing to consider vaccination against COVID 19, adherence factors and reasons for not vaccinating. Materials and methods. A survey on the attitude to vaccination against COVID 19 was prospectively carried out among all pts with CML consulted at the outpatient department of National Research Center for Hematology (Moscow, Russia) who agreed to participate. …”
Enlace del recurso
Enlace del recurso

“…We used 10ng of initial DNA material. Libraries were quantified using Qubit and sequenced on a MiniSeq System in a 2x150 bp run. …”
Enlace del recurso
Enlace del recurso

“…SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13167-021-00267-w.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Secondary objectives were established to identify the risks of acute chronic toxicity risks and to assess colostomy rates. Materials and methods: Patients were treated for biopsy-proven squamous cell cancer (SCC) of the anus at initial or advanced stages. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…STUDY DESIGN, SIZE, DURATION: A population-based case–control GWAS was carried out. PARTICIPANTS/MATERIALS, SETTING, METHODS: We identified PCOS cases from national registers by ICD codes (ICD-10 E28.2, ICD-9 256.4, or ICD-8 256.90), and all remaining women were considered controls. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Six subgroups were identified, depending on pubertal stage at initiation of medical treatment (Tanner stage 2-3, Tanner stage 4-5, adult), and whether hormonal treatment was continued or temporarily stopped prior to gGAS in each of these groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: All transgender women used a combination of estrogens and testosterone suppressing therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Replies were collected between 15 May and 1 July 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: A cross-sectional study was performed to gather data on the current use of endometriosis classification systems, problems encountered and interest in a new simple surgical descriptive system for endometriosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Eligible HCPs and patient advocates were those employed at a fertility clinic or charity, respectively. PARTICIPANTS/MATERIALS, SETTINGS, METHOD: Focus group topic guides progressed from general questions about fertility consultations to if and how the possibility of treatment failure and need for multiple cycles was introduced and discussed in (attended/own) clinics. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TRANSLATION: For the French translation of the abstract see Supplementary Materials section.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The study was carried out according to the Helsinki Declaration and the ICH-Good-Clinical-Practice. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible women were randomized 1:1 to adjuvant treatment with letrozole 5 mg/day or placebo in an antagonist protocol using a fixed dose of recombinant (r) FSH 150 IU/day. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, direct RNA sequencing was applied to ovarian samples from 8 OoGpr54(−/−) and 7 control mice at 6 months of age, and gonadotropin priming for ovulatory induction was conducted in mice (N = 7) from both genotypes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Oocyte-selective ablation of Gpr54 in the oocyte was achieved in vivo by crossing a Gdf9-driven Cre-expressing transgenic mouse line with a Gpr54 LoxP mouse line. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso